Literature DB >> 28372912

Novel scaffold evolution through combinatorial 3D-QSAR model studies of two types of JNK3 inhibitors.

Hoyong Jung1, Waqar Aman2, Jung-Mi Hah3.   

Abstract

JNK3 is an emerging target for neurodegenerative diseases including AD and PD, with histological selectivity. Specifically, in AD, JNK3 is the main protein kinase for APP phosphorylation, which is an important mechanism for Aβ processing, and a biomarker of Alzheimer's disease. Therefore, targeting JNK3 is a reasonable strategy for drug discovery in neurodegenerative diseases. In order to find a novel scaffold for JNK3 inhibitors, we performed 3D-QSAR modeling studies with two different JNK3 inhibitor series. The CoMFA model was obtained with a q2 value of 0.806 and an r2 value of 0.850. Based on CoMFA and CoMSIA models, rational design was conducted and led to a novel scaffold, N-(thiophen-2-yl)-8H-pyrazolo[1,5-a]pyrido[1,2-c]pyrimidine-10-carboxamide.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  3D-QSAR; JNK3; Neurodegenerative disease

Mesh:

Substances:

Year:  2017        PMID: 28372912     DOI: 10.1016/j.bmcl.2017.03.063

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  2 in total

1.  N-Aromatic-Substituted Indazole Derivatives as Brain-Penetrant and Orally Bioavailable JNK3 Inhibitors.

Authors:  Yangbo Feng; HaJeung Park; Jae Cheon Ryu; Sung Ok Yoon
Journal:  ACS Med Chem Lett       Date:  2021-09-21       Impact factor: 4.632

2.  Thiophene-Pyrazolourea Derivatives as Potent, Orally Bioavailable, and Isoform-Selective JNK3 Inhibitors.

Authors:  Yangbo Feng; HaJeung Park; Luke Bauer; Jae Cheon Ryu; Sung Ok Yoon
Journal:  ACS Med Chem Lett       Date:  2020-12-13       Impact factor: 4.345

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.